C: Use with caution if benefits outweigh risks. Animal experiments demonstrate hazard and human research not obtainable or neither animal nor human reports finished.
pentobarbital will lower the extent or outcome of disopyramide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital will reduce the extent or influence of acalabrutinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will reduce the extent or result of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.
pentobarbital will decrease the level or impact of isradipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
pentobarbital will reduce the level or outcome of ethinylestradiol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. The efficacy of hormonal contraceptives may be decreased. Utilization of a nonhormonal contraceptive is usually recommended.
Contraindicated (one)pentobarbital will decrease the level or effect of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with potent CYP3A4 inducers may lead to lessened serum concentrations and lack of antimalarial efficacy
pentobarbital will increase toxicity of methoxyflurane by increasing metabolism. Contraindicated. Greater metabolism of methoxyflurane to nephrotoxic compounds.
To minimize the potential for overdosage or the event of dependence, Restrict the prescribing and dispensing of sedative-hypnotic barbiturates, to the amount expected for get more info the interval right up until another appointment
pentobarbital will lessen the level or result of atogepant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Proposed atogepant dosage with concomitant utilization of sturdy or moderate CYP3A4 inducers is thirty mg or 60 mg qDay.
Keep track of Carefully (one)pentobarbital will decrease the level or influence of fentanyl intranasal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on to a reduce in fentanyl plasma concentrations, lack of efficacy or, possibly, advancement of a withdrawal syndrome in a very patient who has produced physical dependence to fentanyl. Just after stopping a CYP3A4 inducer, given that the effects in the inducer decrease, the fentanyl plasma concentration will maximize which could increase or lengthen both the therapeutic and adverse effects.
buprenorphine subdermal implant and pentobarbital both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom choice treatment method alternatives are insufficient
Contraindicated (one)pentobarbital will reduce the extent or result of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is usually a sensitive CYP3A4 substrate. Coadministration with solid or moderate CYP3A4 inducers is contraindicated.
pentobarbital will minimize the level or impact of nitrendipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.